Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 26, 2024Clinical Pharmacology & TherapeuticsOpen Access

Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CJChanghyeon JeongNHNayoung HanNJNakyung Jeon

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jeong et al. (2024) studied this question.

synapsesocial.com/papers/6a9a44ba2e341dca26e43864https://doi.org/10.1002/cpt.3278
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The PRISMA 2020 statement: An updated guideline for reporting systematic reviews2021 · 11,923 citations
  2. 2Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study2023 · 106 citations
  3. 3Use of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis2023 · 25 citations
  4. 4Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study2023 · 108 citations
  5. 5Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes2023 · 47 citations